A elaboração das Diretrizes para Diagnóstico e Tratamento da COVID-19 é uma resposta rápida ao enfrentamento da COVID-19, diante da declaração de pandemia pela Organização Mundial de Saúde (OMS) e das iniciativas do Ministério da Saúde para enfrentamento dessa nova situação no Brasil. ...
A intensa produção de evidência sobre o assunto nos últimos meses faz destas Diretrizes um documento dinâmico que terá versões provisórias e atualizações periódicas, acompanhando a produção de novas evidências para assim estabelecer recomendações.
more
UNGASS 2016 OUTCOME IMPLEMENTATION
Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
This guide provides an overview of important points to consider in the assessment and treatment of PTSD and ASD in children and adolescents. The practitioner checklist later in this document can help
to guide assessment and treatment planning.
Policy
July 2012
Working Paper No. 3
The shortage of human resources for health, and in particular physicians, is one of the major barriers to achieve universal access to HIV care and treatment. In September 2005, a pilot program of nurse-centered antiretroviral treatment (ART) prescription was launched in three rural primary health ce...nters in Rwanda. We retrospectively evaluated the feasibility and effectiveness of this task-shifting model using descriptive data.
more
With the growing prevalence of type 2 diabetes, particularly in emerging countries, its management in the context of available resources should be considered. International guidelines, while comprehensive and scientifically valid, may not be appropriate for regions such as Asia, Latin America or Afr...ica, where epidemiology, patient phenotypes, cultural conditions and socioeconomic status are different from America and Europe. Although glycaemic control and reduction of micro- and macrovascular outcomes remain essential aspects of treatment, access and cost are major limiting factors; therefore, a pragmatic approach is required in restricted-resource settings. Newer agents, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in particular, are relatively expensive, with limited availability despite potentially being valuable for patients with insulin resistance and cardiovascular complications. This review makes a case for the role of more accessible second-line treatments with long-established efficacy and affordability, such as sulfonylureas, in the management of type 2 diabetes, particularly in developing or restricted-resource countries.
more
The highly complex and largely neglected Chagas disease (CD) has become a global health problem due to population movements between Latin America and non-endemic countries, as well as non-vectorial transmission routes. Data on CD testing and treatment from routine patient care in Germany of almost t...wo decades was collected and analysed.
more
The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form...ed, and different subgroups were created to advise on specific NTDs, including a subgroup working on the human African trypanosomiasis (HAT) diagnostic innovation needs. This group of independent experts included leading scientists, public health officials and endemic-country end-user representatives. Standard WHO Declaration of Interest procedures were followed. A landscape analysis of the available products and of the development pipeline was conducted, and the salient areas with unmet needs were identified.
more